Instructor:
Anthony P. Bossis, PhD

Saturdays:
March 18, 2023 & March 25, 2023
12:30 – 5pm (each day)

Live Online via Zoom (registration is required in order to receive the zoom link)
In-Person (limited capacity)

Registration will close
Friday, March 17, at 1pm

YOU WILL RECEIVE THE ZOOM LINK
BETWEEN 1PM AND 2PM
ON FRIDAY, MARCH 17

Registration is Closed

Separating the science from hype: What does the research evidence show? This two-day course will review the history and scientific findings of psychedelic research, current FDA-approved clinical trials, and the therapeutic implications of psychedelic psychotherapies’ utility in mental health. A detailed review of the history and research with psychedelics for end-of-life existential distress and implications for palliative care will be presented, along with an overview of psychedelic research in other clinical disorders. Additional topics include the implications of psychedelics for studying meaning-making, spirituality, and consciousness research. The course will primarily focus on classic psychedelics, a class of serotonergic compounds that includes psilocybin and will also review research with other compounds.

Learning Objectives: After attending the presentation, participants will be able to
– Identify the primary psychedelic (hallucinogens) used in psychedelic clinical research.
– Demonstrate general knowledge of the scientific findings from psilocybin cancer-anxiety research and other contemporary research findings.
– Identify common features of existential and psychological distress observed in cancer and end-of-life patients.
– Describe and identify the primary components of the psychedelic psychotherapy treatment model including an understanding of set and setting.
– Describe the features of a psychedelic-generated mystical experience (shown to be correlated with enhanced outcomes in some psychedelic therapies).

Note: This course does not provide instruction on how to use psychedelics, provide instruction or training on how to be a psychedelic therapist, or will discuss the use of psychedelics outside of academic clinical research and the history of psychedelics. Most psychedelic drugs are federally identified as Schedule 1 and will be referenced only regarding FDA clinical trials.

Open to:
NPAP Members I $225
Candidates I $225 (register as usual for coursework)
Other Professionals I $285
Student Guest Rate I $120 (Inquiries: [email protected] )
Contribution I Encouraged

9.0 CE contact hours will be granted to participants with documented attendance and complete evaluation form. It is the responsibility of the participants seeking CE credits to comply with these requirements. Upon completion, a Certificate of Attendance will be emailed to all participants.

Bio: Anthony P. Bossis, Ph.D., is a clinical psychologist and clinical assistant professor of psychiatry at NYU School of Medicine, an adjunct professor of classics and religious studies at the University of Ottawa, and an Investigator at The Lundquist Institute for Biomedical Innovation. Since 2006, he has been conducting FDA-approved clinical research with the psychedelic compound psilocybin. Dr. Bossis was director of palliative care research and co-principal investigator on a 2016 clinical trial demonstrating a significant reduction in emotional and existential distress from a single psilocybin session in persons with cancer along with improvements in spiritual well-being and quality of life. He is the study director and lead therapist on a clinical trial investigating a psilocybin-generated mystical experience upon religious leaders. Dr. Bossis is a training supervisor of psychotherapy at NYU-Bellevue Hospital and co-founder and former co-director of the Bellevue Hospital Palliative Care Service. He is on the faculty at The Center for Psychedelic Therapies and Research at the California Institute of Integral Studies. His primary research interests in the study of psychedelics are for the treatment of end-of-life existential distress and to advance our understanding of consciousness, meaning, and spirituality. He maintains a private psychotherapy and consulting practice in NYC.

______________

National Psychological Association for Psychoanalysis is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0139.

National Psychological Association for Psychoanalysis is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed psychoanalysts. #P-0010.

The National Psychological Association for Psychoanalysis, Inc., is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed psychologists #PSY-0137.

National Psychological Association for Psychoanalysis is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed marriage and family therapists #MFT-0093.